Home
FULC
FULC News

Latest Fulcrum Therapeutics Inc. (FULC) News on August 11, 2025

Fulcrum Therapeutics (NASDAQ:FULC) investors are sitting on a loss of 60% if they invested five years ago

Simply Wall St.

a month ago

Fulcrum Therapeutics (NASDAQ:FULC) investors are sitting on a loss of 60% if they invested five years ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory

Insider Monkey

2 months ago

Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

GlobeNewswire

2 months ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

GlobeNewswire

2 months ago

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

MT Newswires

3 months ago

Fulcrum Therapeutics Shares Rise After Upgrade From Leerink

MT Newswires

3 months ago

Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4

MT Newswires

3 months ago

Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade

MT Newswires

3 months ago

Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Participate in Upcoming May Conferences

GlobeNewswire

3 months ago

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ...

GuruFocus.com

3 months ago

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ...

Thomson Reuters StreetEvents

3 months ago

Q1 2025 Fulcrum Therapeutics Inc Earnings Call

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

GlobeNewswire

3 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

GlobeNewswire

4 months ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Simply Wall St.

4 months ago

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

GlobeNewswire

5 months ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

6 months ago

Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

6 months ago

Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Thomson Reuters StreetEvents

6 months ago

Q4 2024 Fulcrum Therapeutics Inc Earnings Call

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

GlobeNewswire

6 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result

GuruFocus.com

6 months ago

Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

GlobeNewswire

6 months ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

6 months ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Fulcrum Therapeutics Insider Ups Holding During Year

Simply Wall St.

6 months ago

Fulcrum Therapeutics Insider Ups Holding During Year

Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago

Simply Wall St.

8 months ago

Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

Zacks

8 months ago

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

Fulcrum Therapeutics to Participate in Upcoming December Conferences

GlobeNewswire

9 months ago

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)

Simply Wall St.

9 months ago

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)

Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...

GuruFocus.com

9 months ago

Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

GlobeNewswire

9 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

GlobeNewswire

9 months ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

GlobeNewswire

9 months ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?

Zacks

10 months ago

Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Simply Wall St.

10 months ago

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

Investor's Business Daily

10 months ago

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...

GuruFocus.com

10 months ago

Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

Zacks

10 months ago

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

GuruFocus.com

10 months ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround

Zacks

10 months ago

Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround

MT Newswires

a year ago

Fulcrum Therapeutics to Cut Jobs, Reprioritize R&D Activities

GuruFocus.com

a year ago

RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares

Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

Zacks

a year ago

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

MT Newswires

a year ago

RBC Downgrades Fulcrum Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $15; Speculative Risk Kept

MT Newswires

a year ago

Top Midday Decliners

Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

Benzinga

a year ago

Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

MT Newswires

a year ago

Piper Sandler Cuts Price Target on Fulcrum Therapeutics to $6 From $16, Maintains Overweight Rating; Shares Plunge

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Cantor Fitzgerald Downgrades Fulcrum Therapeutics to Neutral From Overweight

Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test

BioPharma Dive

a year ago

Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test

MT Newswires

a year ago

Fulcrum Therapeutics Shares Crash Premarket as Clinical Trial of Losmapimod Fails to Meet Primary Endpoint

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

GlobeNewswire

a year ago

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

Zacks

a year ago

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

Zacks

a year ago

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

Benzinga

a year ago

Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

MT Newswires

a year ago

BofA Securities Upgrades Fulcrum Therapeutics to Neutral From Underperform, Raises Price Target to $10 From $5

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

Zacks

a year ago

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

MT Newswires

a year ago

RBC Adjusts Price Target on Fulcrum Therapeutics to $15 From $14, Maintains Outperform, Speculative Risk Rating

JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab

Zacks

a year ago

JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

Zacks

a year ago

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

Zacks

a year ago

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

Zacks

a year ago

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

One Fulcrum Therapeutics Insider Raised Their Stake In The Previous Year

Simply Wall St.

a year ago

One Fulcrum Therapeutics Insider Raised Their Stake In The Previous Year

Addex Stock Soars on Crucial Update From Indivior Research Deal

Zacks

a year ago

Addex Stock Soars on Crucial Update From Indivior Research Deal

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

Zacks

a year ago

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

Fulcrum Therapeutics to Participate in Upcoming September Conferences

GlobeNewswire

a year ago

Fulcrum Therapeutics to Participate in Upcoming September Conferences

Insmed Stock Surges 168% in the Past Six Months: Here's Why

Zacks

a year ago

Insmed Stock Surges 168% in the Past Six Months: Here's Why

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

Zacks

a year ago

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

The Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay

Zacks

a year ago

The Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay

5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts

Zacks

a year ago

5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

Zacks

a year ago

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Zacks

a year ago

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Zacks

a year ago

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

Zacks

a year ago

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

Zacks

a year ago

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

Zacks

a year ago

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

Zacks

a year ago

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

MT Newswires

a year ago

Fulcrum Therapeutics Names Isabel Kalofonos as Chief Commercial Officer, Heather Faulds as Chief Regulatory Affairs Officer

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

GlobeNewswire

a year ago

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

Zacks

a year ago

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

Zacks

a year ago

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Zacks

a year ago

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Zacks

a year ago

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

Zacks

a year ago

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Zacks

a year ago

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Zacks

a year ago

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know

Zacks

a year ago

Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know

Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know

Zacks

a year ago

Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know

Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect?

Zacks

a year ago

Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect?

Fulcrum Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Fulcrum Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

GlobeNewswire

a year ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

Share on Social Networks: